Key facts
- Notable investors include Innovasjon Norge, Oslo Cancer Cluster Incubator, Startuplab Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Thelper
- ·The full record, as it builds
Funding rounds
No funding rounds for Thelper are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Thelper
Operator of antiviral-targeted oncology therapies intended to treat solid tumors by targeting virus-associated markers not present in healthy tissue. The company offers antibody-drug conjugates with humanized antiviral antibodies, viral-target discovery platforms, and cell therapy development programs, enabling oncology researchers and healthcare providers to selectively target multiple tumor types and improve treatment specificity.
- Sector
- Healthcare
- HQ
- Oslo, Norway
- Founded
- 2019
- Employees
- 4
- Website
- thelper.com/
- Ownership
- Privately Held (backing)
Thelper doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Thelper shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Thelper in its N-PORT filings yet. We sweep new filings monthly.